666 related articles for article (PubMed ID: 32667213)
1. Emerging drugs for the treatment of hidradenitis suppurativa.
Folkes AS; Hawatmeh FZ; Wong A; Kerdel FA
Expert Opin Emerg Drugs; 2020 Sep; 25(3):201-211. PubMed ID: 32667213
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
[No Abstract] [Full Text] [Related]
4. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
5. Investigational drugs in clinical trials for Hidradenitis Suppurativa.
Theut Riis P; Thorlacius LR; Jemec GB
Expert Opin Investig Drugs; 2018 Jan; 27(1):43-53. PubMed ID: 29188733
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
Nader A; Beck D; Noertersheuser P; Williams D; Mostafa N
Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
[TBL] [Abstract][Full Text] [Related]
8. Biologic Treatment for Hidradenitis Suppurativa.
Flood KS; Porter ML; Kimball AB
Am J Clin Dermatol; 2019 Oct; 20(5):625-638. PubMed ID: 31140067
[TBL] [Abstract][Full Text] [Related]
9. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
Holcomb ZE; Porter ML; Kimball AB
Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab: A Review in Hidradenitis Suppurativa.
Kim ES; Garnock-Jones KP; Keam SJ
Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
[TBL] [Abstract][Full Text] [Related]
11. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients.
Scheinfeld N
Dermatol Online J; 2013 Apr; 19(4):1. PubMed ID: 24021361
[TBL] [Abstract][Full Text] [Related]
12. Biologic therapies for the treatment of hidradenitis suppurativa.
Rosales Santillan M; Morss PC; Porter ML; Kimball AB
Expert Opin Biol Ther; 2020 Jun; 20(6):621-633. PubMed ID: 32077334
[No Abstract] [Full Text] [Related]
13. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
Harde V; Mrowietz U
J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
[TBL] [Abstract][Full Text] [Related]
14. Use of biological treatments in patients with hidradenitis suppurativa.
Martin-Ezquerra G; Masferrer E; Pujol RM
G Ital Dermatol Venereol; 2017 Aug; 152(4):373-378. PubMed ID: 27982551
[TBL] [Abstract][Full Text] [Related]
15. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology of antibiotic therapy in hidradenitis suppurativa.
Marasca C; Tranchini P; Marino V; Annunziata MC; Napolitano M; Fattore D; Fabbrocini G
Expert Rev Clin Pharmacol; 2020 May; 13(5):521-530. PubMed ID: 32364806
[TBL] [Abstract][Full Text] [Related]
17. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
Porter ML; Golbari NM; Lockwood SJ; Kimball AB
Semin Cutan Med Surg; 2018 Sep; 37(3):182-189. PubMed ID: 30215636
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
[TBL] [Abstract][Full Text] [Related]
19. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
20. A Review of the Current Landscape of Hidradenitis Suppurativa Treatment Development.
Westerkam L; Sayed C
J Drugs Dermatol; 2023 Oct; 22(10):1021-1026. PubMed ID: 37801538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]